124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
Applications of positron-emitting halogens in PET oncology (review).
Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.
(2004). Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer
(1998). Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
(1994). Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy.
Effective dose from radiopharmaceuticals.
Evaluation of dosimetry of radioiodine 964 Eur J Nucl Med Mol Imaging (2008) 35:958–965therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.
(1991). for absorbed dose calculations. New York: The Society of Nuclear Medicine;
(2004). Forga Llenas L, Goni Iriarte MJ, Barberia Layana JJ. Prognostic value of thyroglobulin serum levels and 131I whole body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid
(1987). Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose.
(1985). In vivo imaging of the human thyroid with a positron camera using 124I.
(1994). Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid
(1986). Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients.
(1998). Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
(1988). Investigational study of iodine-124 with a positron camera.
(2007). Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET (/CT) systems.
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
(2006). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce. Thyroid
(1987). Measurement of radiation dose to the thyroid using positron emission tomography.
Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
(1996). Quantitative imaging of iodine-124 with PET.
(1999). Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging
The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
(2008). The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.
(1987). Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.
(1990). Thyroid imaging using positron emission tomography-a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis.
(1997). Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography.
(1986). Tomographic imaging of the human thyroid using 124I.
(2004). Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol